Elizabeth Garrett‐Mayer

20.4k total citations · 3 hit papers
339 papers, 13.1k citations indexed

About

Elizabeth Garrett‐Mayer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Elizabeth Garrett‐Mayer has authored 339 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Oncology, 89 papers in Pulmonary and Respiratory Medicine and 65 papers in Molecular Biology. Recurrent topics in Elizabeth Garrett‐Mayer's work include Cancer Genomics and Diagnostics (45 papers), Lung Cancer Treatments and Mutations (36 papers) and Colorectal Cancer Treatments and Studies (25 papers). Elizabeth Garrett‐Mayer is often cited by papers focused on Cancer Genomics and Diagnostics (45 papers), Lung Cancer Treatments and Mutations (36 papers) and Colorectal Cancer Treatments and Studies (25 papers). Elizabeth Garrett‐Mayer collaborates with scholars based in United States, Netherlands and Canada. Elizabeth Garrett‐Mayer's co-authors include Rebecca Landa, David Wendler, David I. Shalowitz, Michael I. Nishimura, David J. Cole, Mohamed L. Salem, Alberto J. Montero, C. Marcela Díaz‐Montero, Mario A. Eisenberger and Katherine C. Holman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Elizabeth Garrett‐Mayer

328 papers receiving 12.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

2008 992 citations Mohamed L. Salem, Michael I. Nishimura et al. profile →
The Accuracy of Surrogate Decision Makers

2006 682 citations Elizabeth Garrett‐Mayer et al. profile →
Eliminating catheter-related bloodstream infections in the intensive care unit*

2004 666 citations Elizabeth Garrett‐Mayer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth Garrett‐Mayer United States	56	3.8k	3.3k	2.4k	1.9k	1.8k	339	13.1k
David Elashoff United States	65	3.1k 0.8×	4.3k 1.3×	2.2k 0.9×	1.3k 0.7×	2.7k 1.5×	384	14.9k
Hang Lee United States	82	4.2k 1.1×	4.7k 1.4×	3.1k 1.3×	964 0.5×	731 0.4×	440	26.2k
Yutaka Yasui United States	67	5.4k 1.4×	3.3k 1.0×	1.8k 0.8×	494 0.3×	1.2k 0.7×	377	18.4k
Angela DeMichele United States	64	7.5k 2.0×	2.6k 0.8×	4.7k 2.0×	997 0.5×	2.8k 1.6×	308	13.1k
Kevin Stein United States	43	8.4k 2.2×	3.2k 1.0×	3.3k 1.4×	591 0.3×	1.9k 1.1×	112	16.3k
Howard T. Thaler United States	76	5.7k 1.5×	2.3k 0.7×	4.0k 1.7×	1.1k 0.5×	1.1k 0.6×	233	19.6k
Fiona Campbell United Kingdom	64	3.4k 0.9×	2.3k 0.7×	1.2k 0.5×	943 0.5×	1.4k 0.8×	248	14.7k
Neil E. Caporaso United States	72	4.3k 1.1×	7.0k 2.1×	3.6k 1.5×	792 0.4×	3.2k 1.8×	279	17.6k
Joan Montaner Spain	91	1.2k 0.3×	5.5k 1.7×	4.3k 1.8×	1.7k 0.9×	2.3k 1.3×	655	32.8k
William E. Barlow United States	76	7.6k 2.0×	1.5k 0.5×	3.4k 1.4×	292 0.2×	3.5k 2.0×	277	19.9k

Countries citing papers authored by Elizabeth Garrett‐Mayer

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Garrett‐Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Garrett‐Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Garrett‐Mayer more than expected).

Fields of papers citing papers by Elizabeth Garrett‐Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Garrett‐Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Garrett‐Mayer. The network helps show where Elizabeth Garrett‐Mayer may publish in the future.

Co-authorship network of co-authors of Elizabeth Garrett‐Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Garrett‐Mayer. A scholar is included among the top collaborators of Elizabeth Garrett‐Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Garrett‐Mayer. Elizabeth Garrett‐Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kirkwood, M. Kelsey, Erin P. Balogh, Melissa Accordino, et al.. (2025). Where Have We Been and Where Are We Going? The State of the Hematology and Medical Oncologist Workforce in America. JCO Oncology Practice. 21(12). 1775–1785.

Levit, Laura A., Elizabeth Garrett‐Mayer, Jeffrey Peppercorn, & Mark J. Ratain. (2024). Critical importance of correctly defining and reporting secondary endpoints when assessing the ethics of research biopsies. Clinical Trials. 21(5). 650–656.

Thall, Peter F., Elizabeth Garrett‐Mayer, Nolan A. Wages, Susan Halabi, & Ying Kuen Cheung. (2024). Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus. Clinical Trials. 21(3). 267–272. 4 indexed citations

Ganti, Apar Kishor, Michael Rothe, Pam K. Mangat, et al.. (2023). Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 7(7). e2300041–e2300041. 6 indexed citations

Magnuson, Allison, Suanna S. Bruinooge, Harpreet Singh, et al.. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research. 27(9). 2424–2429. 44 indexed citations

Harvey, R. Donald, Suanna S. Bruinooge, Li Chen, et al.. (2021). Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations. Clinical Cancer Research. 27(9). 2430–2434. 29 indexed citations

Hopkins, Ashley M., Ganessan Kichenadasse, Elizabeth Garrett‐Mayer, et al.. (2020). Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. Clinical Cancer Research. 26(13). 3280–3286. 29 indexed citations

Fisher, Julie Gottlieb, David L. Tait, Elizabeth Garrett‐Mayer, et al.. (2020). Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology. 15(6). 733–741. 30 indexed citations

Johnson, Christopher, Brian Riesenberg, Samantha Suriano, et al.. (2018). Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Research. 78(11). 3067–3074. 7 indexed citations

10.

Rachidi, Saleh, Alessandra Metelli, Brian Riesenberg, et al.. (2017). Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Science Immunology. 2(11). 265 indexed citations

11.

Scurti, Gina, Patricia Simms, Elizabeth Garrett‐Mayer, et al.. (2016). Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. Cancer Research. 76(20). 6006–6016. 58 indexed citations

12.

Johnson, Christopher, Brian Riesenberg, Guangfu Li, et al.. (2015). Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent. Cancer Immunology Research. 3(12). 1364–1374. 21 indexed citations

13.

Kesarwani, Pravin, Amir A. Al-Khami, Gina Scurti, et al.. (2014). Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions. Cancer Research. 74(21). 6036–6047. 39 indexed citations

14.

Guest, Stephen T., et al.. (2014). Oncogenic signaling in amphiregulin and EGFR‐expressing PTEN‐null human breast cancer. Molecular Oncology. 9(2). 527–543. 21 indexed citations

15.

Nasarre, Patrick, Robert M. Gemmill, Vincent Potiron, et al.. (2013). Neuropilin-2 Is Upregulated in Lung Cancer Cells during TGF-β1–Induced Epithelial–Mesenchymal Transition. Cancer Research. 73(23). 7111–7121. 55 indexed citations

16.

Smith, B. Douglas, Yvette L. Kasamon, Jeanne Kowalski, et al.. (2010). K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clinical Cancer Research. 16(1). 338–347. 77 indexed citations

17.

Cunningham, Joan E., Alberto J. Montero, Elizabeth Garrett‐Mayer, Hans J. Berkel, & Bert Ely. (2009). Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes & Control. 21(3). 399–409. 33 indexed citations

18.

Armstrong, Andrew J., Elizabeth Garrett‐Mayer, Ronald de Wit, Ian F. Tannock, & Mario A. Eisenberger. (2009). Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Clinical Cancer Research. 16(1). 203–211. 166 indexed citations

19.

Moussa, Omar, Anthony W. Ashton, Mostafa Fraig, et al.. (2008). Novel Role of Thromboxane Receptors β Isoform in Bladder Cancer Pathogenesis. Cancer Research. 68(11). 4097–4104. 52 indexed citations

20.

Armstrong, Andrew J., et al.. (2007). A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Clinical Cancer Research. 13(21). 6396–6403. 282 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact